Tone mix
Week by week 52 weeks
Share of Ionis Pharmaceuticals, Inc. Common Stock's 205 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Dec 29, 2025 · tone +100Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Rating of "Moderate Buy" from Analysts+86
- Week of Oct 13, 2025 · tone 0Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Mirae Asset Global Investments Co. Ltd.-83
- Week of Oct 20, 2025 · tone 0Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares-82
- Week of Jan 26, 2026 · tone +100Ionis Pharmaceuticals (NASDAQ:IONS) Earns Overweight Rating from Analysts at Barclays+79
- Week of Aug 4, 2025 · tone 0Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Position Lifted by Privium Fund Management B.V.-68
- Week of Aug 10, 2026 · tone +49Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives $94.65 Average Target Price from Brokerages+59
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Ionis Pharmaceuticals, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 1 | 0 |
| Last 30 sessions | 6 | +33 |
| Last 90 sessions | 56 | -7 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Monday, November 2, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletReviewing Ionis Pharmaceuticals (NASDAQ:IONS) & Pluri (NASDAQ:PLUR)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Reviewing Ionis Pharmaceuticals (NASDAQ:IONS) & Pluri (NASDAQ:PLUR) | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 20, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletIonis Pharmaceuticals (NASDAQ:IONS) EVP Sells 1,357 Shares of StockNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 1,357 Shares of Stock | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 16, 2026
1 headline, average tone +99: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.finanznachrichten.de · 1 outletIonis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)Positive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG) | www.finanznachrichten.de | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 13, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletIonis Pharmaceuticals (NASDAQ:IONS) & Upstream Bio (NASDAQ:UPB) Head to Head ReviewNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Ionis Pharmaceuticals (NASDAQ:IONS) & Upstream Bio (NASDAQ:UPB) Head to Head Review | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 2, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Rating of "Moderate Buy" from BrokeragesPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Rating of "Moderate Buy" from Brokerages | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Ionis Pharmaceuticals, Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.